Moreover, pacritinib, an oral tyrosine kinase inhibitor, could inhibit the occurrence of GBM by regulating signal transducers and activators of transcription 3 (STAT3))/miR-21/programmed cell death 4 (PDCD4) signaling [71]. Here, PDCD4 is linked to glioblastoma.